Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiae622 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Marni B Jacobs und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology, and Reproductive Sciences, UC San Diego School of Medicine, La Jolla, California, USA. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Neutralizing, Immunoglobulin G, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Patricia Maysent, NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Background
SARS-CoV-2 antibody levels have been proposed as a correlate of protection from infection. Yet, large-scale prospective studies of cost-effective scalable antibody measures as predictors of infection under real-world conditions are limited. We examined whether antibody levels measured by high-throughput variant-specific SARS-CoV-2 anti-spike immunoglobulin G (IgG) and angiotensin-converting enzyme 2 (ACE2) neutralization assays correlate with cell-based neutralizing antibody measurements and whether they can serve as a reasonable correlate of protection from SARS-CoV-2 infection.
Methods
We conducted a large institutional cohort study between January 2022 and March 2023.
Participants
(N = 2513) provided dried blood spot (DBS) samples for assessment of anti-spike IgG and ACE2 inhibition levels through high-throughput assays. Comparison with authentic cell-based SARS-CoV-2 neutralizing antibody assays was conducted with serum samples (n = 105). Associations between antibody levels and risk of infection were evaluated.
Results
Correlation between serum and DBS sampling and between cell-based neutralizing and high-throughput antibody binding assays was high for anti-spike IgG and ACE2 neutralization, though the degree of correlation varied by variant. Longitudinal evaluation suggested that DBS-based IgG and ACE2 inhibition levels were anticorrelated with infection risk, with higher sensitivity noted for ACE2 inhibition and variant-matched measures. IgG and ACE2 inhibition levels decreased over time, with more durable responses observed in participants whose most recent priming event was infection vs vaccination.
Conclusions
Findings suggest that variant-specific SARS-CoV-2 antibody levels may be a useful correlate of protection for infection, which has important implications for vaccination recommendations and evaluating infection risk. High-throughput assays measured via DBS may have utility in timing of boosters at the population or individual level.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Gynecology, and Reproductive Sciences, UC San Diego School of Medicine, La Jolla, California, USA.
- Department of Medicine, UC San Diego School of Medicine, La Jolla, California, USA.
- Department of Surgery, UC San Diego School of Medicine, La Jolla, California, USA.
- Department of Pediatrics, UC San Diego EXCITE Laboratory, La Jolla, California, USA.
- Department of Pathology, UC San Diego School of Medicine, La Jolla, California, USA.
- Department of Pediatrics, UC San Diego School of Medicine, La Jolla, California, USA.
ORCID-Profile: Marni B Jacobs, Alex E Clark, Nicole H Goldhaber, Holly D Valentine, Andrea Rivera, Tom Barber, Jacqueline Holmes, Aaron F Garretson, Aaron F Carlin, Louise C Laurent
Förderung
- Patricia Maysent
- NIH HHS
- NCATS NIH HHS
- Dr Pradeep Khosla
- San Diego chancellor
- University of California
- UC San Diego Health CEO
- Career Award for Medical Scientists from the Burroughs Welcome Fund
Zitieren
APA
Jacobs, M. B., Clark, A. E., Goldhaber, N. H., Valentine, H. D., Rivera, A., Ngo, T., Barber, T., Holmes, J., Manfredi, B., Garretson, A. F., Bray, W., Knight, R., Longhurst, C. A., Carlin, A. F., De Hoff, P., & Laurent, L. C. (2025). Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae622
Vancouver
Jacobs MB, Clark AE, Goldhaber NH, Valentine HD, Rivera A, Ngo T, et al. Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiae622
BibTeX
@article{Jacobs2025,
author = {Jacobs, Marni B and Clark, Alex E and Goldhaber, Nicole H and Valentine, Holly D and Rivera, Andrea and Ngo, Toan and Barber, Tom and Holmes, Jacqueline and Manfredi, Brittany and Garretson, Aaron F and Bray, William and Knight, Rob and Longhurst, Christopher A and Carlin, Aaron F and De Hoff, Peter and Laurent, Louise C},
title = {Antibody Levels From High-Throughput Variant-Specific SARS-CoV-2 Anti-Spike Immunoglobulin G and Angiotensin-Converting Enzyme 2 Neutralization Assays Correlate With COVID-19 Infection Risk in a Large Population},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiae622}
}
EUVIMED